 |
PDBsum entry 1mzc
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Dual protein farnesyltransferase-Geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
|
 |
|
Authors
|
 |
S.J.Desolms,
T.M.Ciccarone,
S.C.Mactough,
A.W.Shaw,
C.A.Buser,
M.Ellis-Hutchings,
C.Fernandes,
K.A.Hamilton,
H.E.Huber,
N.E.Kohl,
R.B.Lobell,
R.G.Robinson,
N.N.Tsou,
E.S.Walsh,
S.L.Graham,
L.S.Beese,
J.S.Taylor.
|
 |
|
Ref.
|
 |
J Med Chem, 2003,
46,
2973-2984.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
A series of novel diaryl ether lactams have been identified as very potent dual
inhibitors of protein farnesyltransferase (FTase) and protein
geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of
Ras. The structure of the complex formed between one of these compounds and
FTase has been determined by X-ray crystallography. These compounds are the
first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in
vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly
lethal.
|
 |
|
|
|
|
 |